Boiron SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000061129
EUR
29.15
-0.85 (-2.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Boiron SA stock-summary
stock-summary
Boiron SA
Pharmaceuticals & Biotechnology
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
Company Coordinates stock-summary
Company Details
2 avenue de l ouest Lyonnais , RONTALON None : 69510
stock-summary
Tel: 33 4 7845610033 478 456100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Thierry Boiron
Chairman of the Board of Directors
Ms. Valerie Lorentz-Poinsot
Chief Executive Officer, General Manager, Director
Laurence Boiron
Director
Anabelle Flory-Boiron
Director
Mr. Jacky Abecassis
Non-Executive Director
Ms. Michele Boiron
Non-Executive Director
Ms. Christine Boutin
Non-Executive Director - Employees Representative
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
167 Million
(Quarterly Results - Dec 2012)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 519 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

4.05%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

1.41